Global Pharmaceutical Group Cuts SAP Maintenance by 60% — While Resisting S/4HANA Migration Pressure

Executive Summary

A global pharmaceutical manufacturer with 14 production facilities across Europe, North America, and Asia was paying €1.84 million annually in SAP maintenance fees for an SAP ECC 6.0 landscape that had been in stable operation for nine years. SAP's annual 2% escalation clause — modest in percentage terms — had added €340,000 to the contract value over that period, with no additional functionality delivered.

More acutely, SAP's Enterprise Support team had begun applying sustained pressure to commit to an S/4HANA migration timeline. The client's CIO and ERP Programme Director were not opposed to S/4HANA in principle — but the business case had not yet been established, the organisation had recently completed a major system consolidation programme, and the IT leadership was not prepared to begin a transformation programme driven by a vendor's revenue targets rather than business strategy.

GoVendorFree was engaged to assess whether independent support was viable for a GxP-regulated SAP landscape — and to deliver the commercial analysis that would support the decision. The assessment confirmed a 60% saving, full GxP compliance capability, and a transition timeline of eight weeks. The client moved to GoVendorFree support in Q2 2025. Twelve months later, the saving had been realised in full and SAP's migration pressure had, by definition, ceased.

The SAP Pressure Campaign

SAP's commercial strategy for ECC 6.0 customers is not subtle. Mainstream Maintenance ends in 2027. Optional Extended Maintenance runs through 2030 at a surcharge. SAP's account teams use this timeline as a lever — not primarily to sell maintenance, but to accelerate S/4HANA licence and transformation services sales. The maintenance contract is the mechanism of leverage.

The client's ERP Programme Director described the dynamic bluntly: "SAP's account team wasn't genuinely interested in our support issues. They were interested in our S/4HANA decision. Every quarterly business review became a migration conversation. They had built a business case based on assumptions about our current costs that were designed to make S/4HANA look attractive — and which didn't hold up to scrutiny."

The client commissioned its own independent S/4HANA business case analysis alongside the GoVendorFree assessment. The conclusion was consistent with what GoVendorFree observes frequently: when the full programme cost of S/4HANA transformation is modelled accurately — including implementation services, data migration, retraining, process redesign, custom code remediation, and productivity loss during cutover — the payback period for most ECC 6.0 clients exceeds seven years. For a company whose ECC 6.0 system was stable, well-supported by internal teams, and deeply integrated with GMP-regulated manufacturing processes, that business case did not close.

The GxP Compliance Question

For pharmaceutical manufacturers, the decision to change any element of a validated system carries compliance implications. SAP ECC 6.0, in this client's environment, was validated under GAMP 5 guidelines and operated as a GxP-critical system for batch record management, quality management (SAP QM), and material management across its manufacturing sites. Any change to the support model required a formal change control assessment.

GoVendorFree's engagement with the client's Head of IT Compliance and QA organisation covered three specific compliance dimensions before the business decision was made:

• Change control for support model transition: GoVendorFree provided documentation supporting the client's formal impact assessment under its existing change control procedure. The assessment confirmed that transitioning the support provider — with no changes to system configuration, no software updates, and no new integrations — represented a low-risk administrative change under GAMP 5 category C.
• Security patch and fix delivery: GoVendorFree's process for delivering security fixes and custom patches for SAP ECC 6.0 follows a documented development, test, and deployment procedure compliant with FDA 21 CFR Part 11 change management expectations. Patch documentation packages include change description, test evidence, deployment instructions, and rollback procedure — meeting the client's internal validation documentation standard.
• Audit trail and support documentation: GoVendorFree's ticketing and incident management system generates a complete, exportable audit trail of all support interactions, fix deployments, and engineering interventions — satisfying the client's obligation to maintain records of changes to validated systems.

Transition Across 14 Sites

The client's SAP landscape was not a single-instance deployment. ECC 6.0 was deployed across three primary instances — one for European operations, one for North America, and one for Asia-Pacific — with satellite systems and interfaces specific to individual manufacturing sites. The transition required GoVendorFree to document the full landscape, establish site-specific contacts and escalation paths, and train the client's internal SAP team on GoVendorFree's support processes.

GoVendorFree assigned a dedicated support team for the client — led by a Principal SAP Engineer with 18 years of SAP ECC experience across pharmaceutical and process manufacturing industries, with specific expertise in SAP QM and PP modules. This was not a rotation resource shared across multiple clients, but a named team with accountability for this client's environment.

The transition ran in parallel with SAP support for eight weeks. During parallel operation, GoVendorFree's team identified three issues with the client's SAP QM configuration that SAP's support team had logged and closed as "not reproducible" in prior months. GoVendorFree's engineers reproduced and resolved two of them within the first three weeks of access.

Results

Twelve months after go-live, the outcomes were as follows:

• Annual SAP-related support cost reduced from €1.84m to €736,000 — a 60% reduction and €1.104m annual saving.
• Three outstanding SAP issues inherited at transition resolved within 45 days, including two QM configuration issues SAP had previously declined to fix.
• Zero GxP non-conformances or audit findings related to the support model change across three internal quality audits and one FDA inspection in the 12-month period.
• S/4HANA migration decision deferred to 2027 review — on the client's timeline, not SAP's.
• Average Priority 1 response time: 11 minutes (GoVendorFree) versus 38 minutes (SAP, prior year average measured by the client's internal KPI tracking).
• SAP account team engagement terminated: without an active SAP maintenance contract, the client now engages SAP licence management teams directly — at arm's length — rather than through an account team with a vested interest in migration sales.

The Lesson for Pharmaceutical Companies

SAP's 2027 maintenance deadline creates a sense of urgency that benefits SAP — and no one else. Pharmaceutical companies operating stable, validated SAP ECC environments are not obligated to migrate on SAP's timeline. The GxP validation argument — that changing support providers introduces compliance risk — is a common objection, and it is addressable. GoVendorFree's pharmaceutical client base includes organisations that have operated independent SAP support for five or more years without a single GxP finding related to the support model.

If your organisation is running SAP ECC in a regulated environment and is being pressured toward an S/4HANA migration you are not ready for, the first step is to understand your commercial alternative. Contact GoVendorFree for a free assessment of your SAP support options.